Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
gilteritinib alk tyrosine kinase receptor small molecule NA drugbank , DGIDB Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 0.56 approved,investigational inhibitor
gilteritinib tyrosine-protein kinase ufo NA Successful target TTD , DGIDB Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 1.7 approved inhibitor
gilteritinib tyrosine-protein kinase ufo NA Successful target TTD , DGIDB Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 1.7 approved unknown
gilteritinib tyrosine-protein kinase receptor ufo small molecule NA drugbank , DGIDB Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 1.7 approved,investigational inhibitor
gilteritinib fms-like tyrosine kinase 3 NA Successful target TTD , DGIDB Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 1.16 approved unknown
gilteritinib receptor-type tyrosine-protein kinase flt3 small molecule NA drugbank , DGIDB Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 1.16 approved,investigational inhibitor
gilteritinib fms-like tyrosine kinase 3 NA Successful target TTD , DGIDB Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 1.16 approved inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
gilteritinib serotonin receptors small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Disease[MeSHID:D004194]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Diagnosis[MeSHID:D003933]
Mutation[MeSHID:D009154]
Blood[MeSHID:D001769]
Bone Marrow[MeSHID:D001853]
Disease Progression[MeSHID:D018450]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
click here to return to the previous page